GNMX - Aevi Genomic Medicine, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
15,394
22,299
25,176
28,552
18,356
Selling General and Administrative
7,085
8,663
9,524
13,523
12,954
Total Operating Expenses
22,479
30,962
34,700
41,879
28,398
Operating Income or Loss
-22,479
-30,962
-34,700
-41,879
-28,398
Interest Expense
-
1
3
15
20
Total Other Income/Expenses Net
-
-
-4
5
-8,170
Income Before Tax
-22,359
-30,775
-34,714
-41,888
-37,975
Income Tax Expense
-
0
0
16
17
Income from Continuing Operations
-22,359
-30,775
-34,714
-41,904
-37,992
Net Income
-22,359
-30,775
-34,714
-41,904
-37,992
Net Income available to common shareholders
-22,359
-30,775
-34,714
-41,904
-37,992
Reported EPS
Basic
-
-0.50
-0.83
-1.19
-1.42
Diluted
-
-0.50
-0.83
-1.19
-1.45
Weighted average shares outstanding
Basic
-
61,382
41,676
35,162
26,784
Diluted
-
61,382
41,676
35,162
26,846
EBITDA
-
-30,709
-34,599
-41,879
-28,398